Cure My Disease

Don't miss your cure!

 Log in / Sign up

New shot aims to tame ulcerative colitis Flare-Ups

NCT ID NCT07463183

Recruiting now Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 31, 2026 · Updated 7 times

Summary

This study tests whether MK-8690, a drug given as a shot, can help people with moderate-to-severe ulcerative colitis achieve remission. About 100 adults who haven't responded well to other treatments will receive either MK-8690 or a placebo. The main goal is to see if more people on the drug reach clinical remission after 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
MK-8690 (also called PRA052), a drug given as a shot under the skin
What this could lead to
If it works, this could point toward a new treatment option for people with moderate-to-severe ulcerative colitis who haven't responded to other therapies.
What could go wrong
This is an early Phase 2a trial with only 100 participants, so results may not apply to everyone. The drug could cause side effects or fail to show benefit over placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLITIS, ULCERATIVE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLITIS, ULCERATIVE ULCERATIVE COLITIS

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • BVL Research - Kansas ( Site 1054)

    RECRUITING

    Liberty, Missouri, 64068, United States

  • Clinnova Research ( Site 1042)

    RECRUITING

    Anaheim, California, 92805, United States

  • EB Group Sp. Z o.o. Centrum Zdrowia MDM ( Site 1449)

    RECRUITING

    Warsaw, Masovian Voivodeship, 00-189, Poland

  • Evangelismos General Hospital of Athens ( Site 1362)

    RECRUITING

    Athens, Attica, 10676, Greece

  • Gastroenterology Associates of Central Georgia ( Site 1060)

    RECRUITING

    Macon, Georgia, 31201, United States

  • Huddersfield Royal Infirmary ( Site 1522)

    RECRUITING

    Huddersfield, York, HD3 3EA, United Kingdom

  • Kangbuk Samsung Hospital ( Site 1601)

    RECRUITING

    Seoul, 03181, South Korea

  • Korea University Ansan Hospital ( Site 1603)

    RECRUITING

    Ansan-si, Kyonggi-do, 15355, South Korea

  • Medical Network Spółka z o.o. WIP Warsaw IBD Point Profesor Kierkuś ( Site 1448)

    RECRUITING

    Warsaw, Masovian Voivodeship, 04-501, Poland

  • Nature Coast Clinical Research ( Site 1045)

    RECRUITING

    Inverness, Florida, 34452, United States

  • Peak Gastroenterology Associates ( Site 1052)

    RECRUITING

    Colorado Springs, Colorado, 80907, United States

  • Radboudumc ( Site 1650)

    RECRUITING

    Nijmegen, Gelderland, 6525 GA, Netherlands

  • Research Associates of South Florida - Miami - Southwest 8th Street ( Site 1072)

    RECRUITING

    Miami, Florida, 33134, United States

  • South Denver Gastroenterology, PC ( Site 1068)

    RECRUITING

    Englewood, Colorado, 80113, United States

  • Tulane University School of Medicine ( Site 1073)

    RECRUITING

    New Orleans, Louisiana, 70112, United States

  • University of Kansas Medical Center ( Site 1077)

    RECRUITING

    Kansas City, Kansas, 66160, United States

  • Wonju Severance Christian Hospital ( Site 1602)

    RECRUITING

    Wŏnju, Kang-won-do, 26426, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.